

Version 2.0	Revision Date: 04/09/2021	SDS Number: 4944874-00004	Date of last issue: 10/10/2020 Date of first issue: 09/30/2019
SECTION	1. IDENTIFICATION		
Produ	uct name	: Olmesartan / A zide Formulatic	mlodipine Besylate (3.5%) / Hydrochlorothia- n
Manu	afacturer or supplier	s details	
Comp Addre	pany name of supplier ess	: 30 Hudson Stre	eet, 33nd floor w Jersey, U.S.A 07302
Telep	hone	: 551-430-6000	
	gency telephone	: 215-631-6999	
E-ma	il address	: EHSSTEWARD	0@organon.com

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accord 1910.1200) Combustible dust	dan	ce with the OSHA Hazard Communication Standard (29 CFR
Eye irritation	:	Category 2A
Reproductive toxicity	:	Category 1A
Specific target organ toxicity - repeated exposure	:	Category 1 (Kidney, Parathyroid gland)
GHS label elements		
Hazard pictograms	:	
Signal Word	:	Danger
Hazard Statements	:	May form combustible dust concentrations in air. H319 Causes serious eye irritation. H360D May damage the unborn child. H372 Causes damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.
Precautionary Statements	:	Prevention:
		 P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe dust. P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P280 Wear protective gloves, protective clothing, eye protection



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 2.0	Revision Date: 04/09/2021	SDS Number: 4944874-00004	Date of last issue: 10/10/2020 Date of first issue: 09/30/2019				
II		and face protec	tion.				
		Response:					
	P305 + P351 + P338 IF IN EYES: Rinse cautiously with wa for several minutes. Remove contact lenses, if present and to do. Continue rinsing. P308 + P313 IF exposed or concerned: Get medical attent P337 + P313 If eye irritation persists: Get medical attentior						
		Storage:					
		P405 Store lock	P405 Store locked up.				
		Disposal:					
		P501 Dispose o disposal plant.	f contents and container to an approved waste				
Othor	hazarda						

Other hazards

Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture	: Mixture	
Components		
Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 30 - < 50
Starch	9005-25-8	>= 30 - < 50
Olmesartan	144689-63-4	>= 10 - < 20
Hydrochlorothiazide	58-93-5	>= 5 - < 10
Amlodipine Besylate	652969-01-2	>= 1 - < 5

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice	 In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice. 	I
If inhaled	: If inhaled, remove to fresh air. Get medical attention.	
In case of skin contact	 In case of contact, immediately flush skin with soap and plent of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse. 	ty
In case of eye contact	 In case of contact, immediately flush eyes with plenty of wate for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention. 	r
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention.	



Version 2.0	Revision Date: 04/09/2021	SDS Number: 4944874-00004	Date of last issue: 10/10/2020 Date of first issue: 09/30/2019
Most important symptoms and effects, both acute and delayed		: Causes serious May damage th	•
	ction of first-aiders to physician	the skin. : First Aid respon and use the rec when the poten	st can cause mechanical irritation or drying of ders should pay attention to self-protection, ommended personal protective equipment tial for exposure exists (see section 8). atically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	High volume water jet
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Do not use a solid water stream as it may scatter and spread fire. Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides Nitrogen oxides (NOx) Chlorine compounds Sulfur oxides
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for	:	Sweep up or vacuum up spillage and collect in suitable



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
2.0	04/09/2021	4944874-00004	Date of first issue: 09/30/2019
contaiı	nment and cleaning up	with compressed Dust deposits she surfaces, as thes released into the Local or national disposal of this m employed in the o determine which Sections 13 and	f dust in the air (i.e., clearing dust surfaces

SECTION 7. HANDLING AND STORAGE

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding
Local/Total ventilation	:	and bonding, or inert atmospheres. If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	:	Do not get on skin or clothing. Do not breathe dust. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.
Conditions for safe storage	:	Keep in properly labeled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.
Materials to avoid	:	Do not store with the following product types: Strong oxidizing agents Organic peroxides Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of	Control parame- ters / Permissible	Basis
------------	---------	------------------------	---------------------------------------	-------



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Vers 2.0		evision Date: 4/09/2021	-	DS Number: 944874-00004		t issue: 10/10/2020 t issue: 09/30/2019	
							_
, la					exposure)	concentration	
	Cellulose			9004-34-6	TWA	10 mg/m ³	ACGIH
					TWA (Res-	5 mg/m ³	NIOSH REL
					pirable)	_	
I					TWA (total)	10 mg/m ³	NIOSH REL
1					TWA (total	15 mg/m ³	OSHA Z-1
					dust)	, s	
lt It					TWA (respir-	5 mg/m ³	OSHA Z-1
					able fraction)	- 5	
I	Starch			9005-25-8	TWA	10 mg/m ³	ACGIH
					TWA (Res-	5 mg/m ³	NIOSH REL
					pirable)	U U	
					TWA (total)	10 mg/m ³	NIOSH REL
1					TWA (total	15 mg/m ³	OSHA Z-1
					dust)		
					TWA (respir-	5 mg/m ³	OSHA Z-1
					able fraction)		
T II	Olmesarta	an		144689-63-4	TWA	30 µg/m3 (OEB 3)	Internal
					Wipe limit	300 µg/100 cm ²	Internal
П	Hydrochlo	orothiazide		58-93-5	TŴA	100 µg/m3 (OEB	Internal
	-					2)	
Π	Amlodipin	e Besylate		652969-01-2	TWA	20 µg/m3 (OEB 3)	Internal
					Wipe limit	100 µg/100 cm ²	Internal

Engineering measures Use feasible engineering controls to minimize exposure to 1 compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Personal protective equipment Respiratory protection General and local exhaust ventilation is recommended to : maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection. Hand protection Material Chemical-resistant gloves Eye protection Wear safety glasses with side shields or goggles. 2 If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
2.0	04/09/2021	4944874-00004	Date of first issue: 09/30/2019
	nd body protection ne measures	eye flushing syst working place. When using do n Wash contamina The effective ope engineering cont appropriate dego	emical is likely during typical use, provide ems and safety showers close to the not eat, drink or smoke. ted clothing before re-use. eration of a facility should include review of rols, proper personal protective equipment, owning and decontamination procedures, e monitoring, medical surveillance and the

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	tablet
Color	:	No data available
Odor	:	No data available
Odor Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	No data available
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 2.0	Revision Date: 04/09/2021	SDS Number: 4944874-00004	Date of last issue: 10/10/2020 Date of first issue: 09/30/2019
Partition coefficient: n- octanol/water Autoignition temperature Decomposition temperature		 Not applicabl No data avail No data avail 	able
Viscosity Viscosity, kinematic Explosive properties		: Not applicabl : Not explosive	
Oxidizing properties Molecular weight Particle size		The substanceNo data availNo data avail	

SECTION 10. STABILITY AND REACTIVITY

Reactivity Chemical stability Possibility of hazardous reac- tions	:	Not classified as a reactivity hazard. Stable under normal conditions. Dust can form an explosive mixture in air. Can react with strong oxidizing agents.
Conditions to avoid Incompatible materials Hazardous decomposition products	:	Avoid dust formation. Oxidizing agents No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation		
Skin contact		
Ingestion		
Eye contact		

Acute toxicity

Not classified based on available information.

Product:

Method: Calculation method	Acute oral toxicity	:	Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method
----------------------------	---------------------	---	--

Components:

Cellulose:		
Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5.8 mg/l Exposure time: 4 h



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

ersion)	Revision Date: 04/09/2021	-	9S Number: 44874-00004	Date of last issue: 10/10/2020 Date of first issue: 09/30/2019
II			Test atmosphere:	dust/mist
Acute	dermal toxicity	:	LD50 (Rabbit): > 2	2,000 mg/kg
Starch	ו:			
Acute	oral toxicity	:	LD50 (Rat): > 5,00	00 mg/kg
Acute	dermal toxicity	:	LD50 (Rabbit): > 2	2,000 mg/kg
Olmes	sartan:			
Acute	oral toxicity	:	LD50 (Rat): > 2,00	00 mg/kg
			LD50 (Mouse): > 2	2,000 mg/kg
			LD50 (Dog): > 1,5	00 mg/kg
Acute	inhalation toxicity	:	Remarks: No data	a available
Acute	dermal toxicity	:	Remarks: No data	a available
Hydro	chlorothiazide:			
Acute	oral toxicity	:	LD50 (Rat): > 2,75	50 mg/kg
			LD50 (Mouse): > 2	2,830 mg/kg
	toxicity (other routes of istration)	:	LD50 (Rat): 990 m Application Route	
			LD50 (Mouse): 59 Application Route	
Amloo	dipine Besylate:			
Acute	oral toxicity	:	LD50 (Rat): 393 m	ng/kg
	corrosion/irritation assified based on availa	ble	information.	
<u>Comp</u>	onents:			
	sartan:		.	
Rema	rks	:	No data available	
Hydro	chlorothiazide:			
Specie Result		:	Rabbit No skin irritation	

Causes serious eye irritation.



Version 2.0	Revision Date: 04/09/2021	SDS Number: 4944874-00004	Date of last issue: 10/10/2020 Date of first issue: 09/30/2019
<u>Comp</u>	oonents:		
Starc	h:		
Speci Resul		: Rabbit : No eye irritati	on
Olme	sartan:		
Speci Resul Metho	lt	: Rabbit : Moderate eye : Draize Test	irritation
Hydro	ochlorothiazide:		
Speci Resul		: Rabbit : Mild eye irrita	tion
Amlo	dipine Besylate:		
Speci Resul		: Rabbit : Severe irritati	on
Resp	iratory or skin sensi	tization	
Not cl Resp	sensitization lassified based on ava iratory sensitization lassified based on ava		
<u>Comp</u>	<u>oonents:</u>		
Starc Test ⊺ Route Speci Resul	Гуре s of exposure es	: Maximization : Skin contact : Guinea pig : negative	Test
Olme	sartan:		
Route Rema	es of exposure arks	: Skin contact : No data avail	able
	cell mutagenicity assified based on ava	ailable information.	
	oonents:		
Cellu	lose:		
	toxicity in vitro	: Test Type: Ba Result: negat	acterial reverse mutation assay (AMES)
			vitro mammalian cell gene mutation test



rsion)	Revision Date: 04/09/2021	SDS Number: 4944874-00004	Date of last issue: 10/10/2020 Date of first issue: 09/30/2019
Genot	oxicity in vivo	cytogenetic Species: Mo	buse Route: Ingestion
Starcl	h:		
Genot	oxicity in vitro	: Test Type: I Result: neg	Bacterial reverse mutation assay (AMES) ative
Olme	sartan:		
Genot	oxicity in vitro	: Test Type: I Result: neg	Bacterial reverse mutation assay (AMES) ative
		Test Type: I Result: neg	Mutagenicity (in vitro mammalian cytogenetic test) ative
			Chromosome aberration test in vitro n: Chinese hamster lung cells tive
		Test Type: I Result: neg	Mouse Lymphoma ative
Genot	oxicity in vivo	Species: Mo	one marrow Route: Oral
	cell mutagenicity - sment	: Weight of e cell mutage	vidence does not support classification as a germ n.
Hydro	ochlorothiazide:		
	oxicity in vitro	: Test Type: I Result: neg	Bacterial reverse mutation assay (AMES) ative
			Chromosomal aberration n: Chinese hamster ovary cells ative
			sister chromatid exchange assay n: Chinese hamster ovary cells tive
		Test Type: i Test system Result: posi	n: mouse lymphoma cells



Version 2.0	Revision Date: 04/09/2021	SDS Number: 4944874-00004	Date of last issue: 10/10/2020 Date of first issue: 09/30/2019
		Species: Chine Cell type: Bone Result: negativ Test Type: in v Species: Mous Cell type: Bone Result: negativ	e marrow re rivo assay se e marrow
	cell mutagenicity - ssment	: Weight of evide cell mutagen.	ence does not support classification as a germ
Δmlo	dipine Besylate:		
	toxicity in vitro	: Test Type: Bad Result: negativ	cterial reverse mutation assay (AMES) /e
		Test Type: Chi Result: negativ	romosome aberration test in vitro re
Carci	nogenicity		
	lassified based on availa	able information.	
Com	oonents:		
Cellu	loso		
Speci		: Rat	
	cation Route	: Ingestion	
	sure time	: 72 weeks	
Resu		: negative	
Olme	sartan:		
Speci		: Rat	
	cation Route	: Oral	
Expo	sure time	: 2 Years	
Resu	lt	: negative	
Speci	es	: Mouse	
Applie	cation Route	: Oral	
Expo	sure time	: 6 Months	
Resu	lt	: negative	
Hydro	ochlorothiazide:		
Speci		: Mouse, female	
		: Oral	
Expo	cation Route sure time	: 2 Years	
Resu	lt	: negative	
Speci	es	: Mouse, male	
	cation Route	: Oral	
Expo	sure time	: 2 Years	
Resu		: equivocal	



	Revision Date: 04/09/2021	SDS Number: 4944874-00004	Date of last issue: 10/10/2020 Date of first issue: 09/30/2019
Species Applicati Exposur Result	on Route e time	: Rat, male and f : Oral : 2 Years : negative	emale
Amlodip	oine Besylate:		
Species Applicati Exposur Result	Application Route Exposure time		
Species Applicati Exposur Result	on Route e time	: Rat : Oral : 2 Years : negative	
IARC	Group 2B: Pc Hydrochloroth	ssibly carcinogenic t niazide	o humans 58-93-5
II OSHA		nt of this product pres st of regulated carcin	sent at levels greater than or equal to 0.1% is ogens.
NTP			ent at levels greater than or equal to 0.1% is d carcinogen by NTP.
-	uctive toxicity hage the unborn child hents:	l.	
Cellulos	e:		
Effects c	n fertility	: Test Type: One Species: Rat Application Rou Result: negative	te: Ingestion
Effects o	n fetal development	: Test Type: Fert Species: Rat Application Rou Result: negative	
Olmesa	rtan:		
	n fertility	: Test Type: Fert Species: Rat Application Rou Fertility: NOAEI Result: No effect	te: Oral .: 1,000 mg/kg body weight
Effects c	n fetal development	: Test Type: Dev Species: Rat Application Rou	
		12 / 20	



Version 2.0	Revision Date: 04/09/2021	SDS Number:Date of last issue: 10/10/20204944874-00004Date of first issue: 09/30/2019	
		Dose: 1000 milligram per kilogram Result: No teratogenic effects.	
		Test Type: Development Species: Rabbit Application Route: Oral Dose: 1 milligram per kilogram Result: No teratogenic effects.	
		Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: >= 1.6 mg/kg body v Symptoms: Malformations were observed., Reduced weight Result: Effects on postnatal development.	
Repr sessi	oductive toxicity - As- nent	: Positive evidence of adverse effects on development human epidemiological studies.	from
•• Hvdr	ochlorothiazide:		
	ts on fertility	: Test Type: Fertility Species: Rat, male and female Application Route: oral (feed) Fertility: NOAEL: 4 mg/kg body weight Result: Effects on fertility.	
		Test Type: Fertility Species: Mouse, male and female Application Route: oral (feed) Fertility: NOAEL: 100 mg/kg body weight Result: Effects on fertility.	
Effec	ts on fetal development	 Test Type: Development Species: Mouse Application Route: Oral Developmental Toxicity: NOAEL: 3,000 mg/kg body v Result: No teratogenic effects. 	veight
		Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 1,000 mg/kg body v Result: No teratogenic effects.	veight
Amlo	odipine Besylate:		
Effec	ts on fertility	 Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Fertility: NOAEL: 10 mg/kg body weight Result: No effects on fertility. 	



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
2.0	04/09/2021	4944874-00004	Date of first issue: 09/30/2019
Effects	on fetal development	Species: Rabbit Application Route Fertility: NOAEL: Result: No effect Test Type: Embr Species: Rat Application Route Developmental T Result: Effects of Test Type: Embr Species: Rabbit Application Route Developmental T Result: No effect Test Type: Embr Species: Mouse Application Route Developmental T Result: Effects of	25 mg/kg body weight s on fertility. yo-fetal development e: Ingestion foxicity: LOAEL: 10 mg/kg body weight in fetal development. yo-fetal development e: Ingestion foxicity: NOAEL: 10 mg/kg body weight s on fetal development. yo-fetal development

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.

Components:

Hydrochlorothiazide:

Target Organs	:	Kidney, Parathyroid gland
Assessment	:	Causes damage to organs through prolonged or repeated
		exposure.

Repeated dose toxicity

Components:

Cellulose:

Species NOAEL	:	Rat
NOAEL	:	>= 9,000 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days

Starch:

Species NOAEL Application Route Exposure time	:	Rat
NOAEL	:	>= 2,000 mg/kg
Application Route	:	Skin contact
Exposure time	:	28 Days



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

ersion .0	Revision Date: 04/09/2021		DS Number: 44874-00004	Date of last issue: 10/10/2020 Date of first issue: 09/30/2019
Metho	od	:	OECD Test Gui	deline 410
Olme	sartan:			
Speci	es	:	Rat	
NOAE	EL	:	2,000 mg/kg	
	cation Route	:	Oral	
	sure time	:	24 Months	
Rema	irks	:	No significant a	dverse effects were reported
Hydro	ochlorothiazide:			
Speci	es	:	Rat, male and f	emale
LÒAE		:	10 mg/kg	
	ation Route	:	Oral	
	sure time	:	2 у	
Targe	t Organs	:	Kidney, Parathy	vroid gland
Speci	es	:	Mouse, male ar	nd female
NOAE		:	300 - 550 mg/k	9
	cation Route	:	Oral	
	sure time	:	2 y	
Rema	irks	:	No significant a	dverse effects were reported
Speci	es	:	Dog	
		:	50 - 200 mg/kg	
	ation Route	:	Oral	
	sure time	-	9 Months	a d
Targe	t Organs	-	Parathyroid glai	na
Amlo	dipine Besylate:			
Speci	es	:	Rat	
NOAE		:	15 mg/kg	
	cation Route	:	Oral	
Expos	sure time	:	90 d	
Rema	irks	:	No significant a	dverse effects were reported
Aspir	ation toxicity			
Not cl	assified based on av	ailable	information.	
<u>Comp</u>	oonents:			
Hydro	ochlorothiazide:			

Experience with human exposure

Components:

Olmesartan:

	:	Symptoms: Eye irritation
Ingestion	:	Symptoms: hypotension
l		Remarks: May cause harm to the unborn child.



Version 2.0	Revision Date: 04/09/2021	SDS Number: 4944874-00004	Date of last issue: 10/10/2020 Date of first issue: 09/30/2019			
П		Based on H	uman Evidence			
Hydro	ochlorothiazide:					
Eye contact Ingestion		: Symptoms:	Symptoms: Eye irritation Symptoms: Dizziness, Headache, Fatigue, Nausea, Ab- dominal pain, hypotension, dry mouth, electrolyte imbalance, eye pain			
Amlo	dipine Besylate:					
Eye contact Ingestion		: Symptoms:	Symptoms: Severe irritation Symptoms: Nausea, Abdominal pain, Fatigue, Headache, Edema, Palpitation			
SECTION	12. ECOLOGICAL IN	IFORMATION				
Ecoto	oxicity					
Comp	oonents:					
Cellu	lose:					
Toxici	ty to fish	Exposure tir	as latipes (Japanese medaka)): > 100 mg/l ne: 48 h ased on data from similar materials			
Hydro	ochlorothiazide:					
Toxici	ty to fish	: LC50 (Pime	phales promelas (fathead minnow)): > 500 mg/l			

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 500 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 500 mg/l Exposure time: 48 h

Amlodipine Besylate:

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): 2.7 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 3.2 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	:	IC50 (Pseudokirchneriella subcapitata (green algae)): 5.6 mg/l Exposure time: 72 h Method: OECD Test Guideline 201

Persistence and degradability

Components:

Cellulose: Biodegradability	:	Result: Readily biodegradable.
Hydrochlorothiazide: Stability in water	:	Hydrolysis: 46.2 %(96 h)



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 2.0	Revision Date: 04/09/2021	SDS Number: 4944874-00004	Date of last issue: 10/10/2020 Date of first issue: 09/30/2019	
 Bioac	cumulative potentia	1		
Comp	oonents:			
Partiti	dipine Besylate: on coefficient: n- ol/water	: log Pow: 3		
	ity in soil ta available			
	adverse effects ta available			

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues	:	Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste
		handling site for recycling or disposal.
		If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.




Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 2.0	Revision Date: 04/09/2021	SDS Number: 4944874-00004	Date of last issue: 10/10/2020 Date of first issue: 09/30/2019	
SAR	A 311/312 Hazards			
SAR	A 313	known CAS i	does not contain any chemical components with numbers that exceed the threshold (De Minimis) els established by SARA Title III, Section 313.	
US S	tate Regulations			
Penn	sylvania Right To Kno	ow		
	Cellulose Starch Olmesartan Hydrochlorothiazid Croscarmellose so Amlodipine Besyla	odium	9004-34-6 9005-25-8 144689-63-4 58-93-5 74811-65-7 652969-01-2	
Calif	ornia Permissible Exp	osure Limits for C	chemical Contaminants	
	Cellulose Starch		9004-34-6 9005-25-8	
The ingredients of this product are reported in the following inventories:				
AICS		: not determine	ed	
DSL		: not determine	ed	
IECS	С	: not determine	ed	

SECTION 16. OTHER INFORMATION

Further information





ACGIH NIOSH REL OSHA Z-1	:	USA. ACGIH Threshold Limit Values (TLV) USA. NIOSH Recommended Exposure Limits USA. Occupational Exposure Limits (OSHA) - Table Z-1 Lim- its for Air Contaminants
ACGIH / TWA NIOSH REL / TWA		8-hour, time-weighted average Time-weighted average concentration for up to a 10-hour
OSHA Z-1 / TWA	:	workday during a 40-hour workweek 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic sub-



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
2.0	04/09/2021	4944874-00004	Date of first issue: 09/30/2019

stance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG -United Nations Recommendations on the Transport of Dangerous Goods: vPvB - Very Persistent and Verv Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/

Revision Date 04/09/2021

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8